Wolverine

Where the name "Wolverine" comes from

"Wolverine" is community shorthand for pairing BPC-157 with TB-500 after an injury. The name is a reference to a comic-book character whose defining trait is a healing factor that repairs damage faster than a person's would. Peptide Health Lab neither coined the name nor endorses it, and the reference is the clearest possible statement of what people hope the pair does rather than of anything that has been demonstrated.

There is no published paper that proposes the combination or introduces the term. What the name has instead is a reason for existing: these are the two compounds most often discussed for soft-tissue injury, and combining them is the obvious move for anyone who has read about both. A 2026 narrative review of peptides in sports medicine describes the resulting market directly: demand for accelerated injury recovery has grown far faster than the evidence base beneath it, a parallel market of unapproved compounds has grown to meet that demand, and the placebo response, amplified by social media, is treated by the authors as a genuine mediator of the apparent effect.^[9]

One thing belongs at the top of this page rather than at the bottom of it, because of who reads a page called Wolverine: both components are prohibited in tested sport at all times. BPC-157 is named under section S0 of the World Anti-Doping Agency Prohibited List and TB-500 by name under section S2.3. If you compete under anti-doping rules at any level, the decision is made and no evidence question follows it. The detail is in the final section.

What's in it and why people combine them

BPC-157 is the tendon component. In rats whose Achilles tendon was sharply detached from the calcaneal bone, a transection that does not heal on its own, daily intraperitoneal BPC-157 improved the Achilles functional index, load to failure, stiffness, and Young's elasticity modulus, produced better-organized collagen fibres and more type I collagen, and substantially reduced the healing impairment caused by concurrent methylprednisolone.^[1] Its rodent literature also extends to skin: topical treatment accelerated closure in an alkali-burn model with more granulation tissue, re-epithelialization, and collagen deposition, and increased endothelial proliferation and tube formation in culture.^[4]

TB-500 is the migration-and-angiogenesis component, and it is a seven-residue fragment of thymosin β4, a 43-amino-acid protein released by platelets at an injury site. The parent protein accelerated dermal healing across a range of preclinical models and went into phase 2 trials in chronic human wounds.^[6] In muscle, six months of thymosin β4 in exercised dystrophin-deficient mice significantly increased regenerating skeletal muscle fibres, and did not significantly improve grip strength, systolic cardiac function, or fibrosis.^[3] Both halves of that result belong on this page.

The rationale for pairing them is complementary mechanism: collagen organization and tendon-to-bone healing from one, cell migration and vascularization from the other. It is a reasonable hypothesis. Until 2026 it was only a hypothesis.

What the evidence says about the combination

Unusually for a community stack, this one has been tested. In 2026, thirty-two male Sprague-Dawley rats underwent standardized Achilles tendon transection and repair and were randomized into four groups of eight: control, BPC-157 alone, TB-500 alone, and both peptides together, dosed intraperitoneally for four weeks. The study measured maximum load to failure biomechanically and scored tendon architecture histologically and immunohistochemically.

The results are worth reading carefully, because they do not say what the name implies. Both peptides improved histopathological parameters relative to control. TB-500 reached statistical significance on maximum load to failure and on total Bonar and Movin scores; BPC-157 alone was numerically better without reaching significance on total scores. And the combined arm did not confer any additional benefit compared with either agent alone. The authors suggest that the absence of an additive effect may reflect convergence on shared downstream pathways, and say explicitly that this hypothesis requires further confirmation.^[2]

That is one exploratory study, in rats, with eight animals per group, over four weeks, on a surgically transected tendon. It is not evidence that the combination is useless in humans, because nothing in this literature is evidence about humans. But it is the only published attempt to answer the question the name asks. Is the pair better than the parts? Its answer was no.

The only human report anywhere near the combination is a retrospective chart review at a single clinic, in which sixteen patients who had received intra-articular injections were reached by telephone and asked about their knee pain. Twelve had received BPC-157 alone and four had received BPC-157 together with thymosin β4; three of those four reported improvement. There was no control group, no randomization, no validated outcome instrument, and no imaging.^[7] Four patients surveyed by phone is not a combination study.

Where the evidence is weak

No human trial has measured repair for either compound. Not one randomized controlled trial has tested BPC-157 or TB-500 against a healing, function, or return-to-play endpoint in a person. An independent 2025 literature and patent review of BPC-157 states the position without hedging: it has not been approved by the FDA or other regulators because sufficient and comprehensive clinical studies confirming benefit in humans do not exist.^[8]

The one direct test of the combination was null on the thing the combination is for. Adding the second peptide did not improve on the first in the only published head-to-head design.^[2] Any argument for the pair has to start by getting past that.

TB-500 is not the molecule in the human trials. The venous-ulcer programme that gives this component its credibility randomized 73 patients to topical full-length thymosin β4 and described its own efficacy findings as suggestive.^[5] The fragment has never been compared with the parent protein head to head, and none of that work studied tendon, muscle, or athletic recovery.

The rodent tendon models are severe injuries, not training load. A sharply transected Achilles tendon in a rat is a model of a surgical injury that cannot heal on its own.^[1] It is not a model of a hamstring strain, a tendinopathy that developed over a season, or ordinary soreness between sessions. Nothing in this literature models those at all.

A histological change is not a functional one. The muscle result that gets quoted for TB-500 is an increase in regenerating fibres in dystrophic mice, in animals whose grip strength did not improve.^[3] Counting fibres and getting strength back are different endpoints.

Long-term safety is unstudied, and the shared proposed mechanism across both compounds is angiogenesis, which is a reason to raise personal or family history of malignancy with a clinician rather than to settle it from a page.^[9]

Questions to bring to a provider

The useful version of this conversation is not "should I run Wolverine." It is "here is the injury, here is what I want back, and here is what has actually been shown to get me there."

• What is the working diagnosis, and what does the standard-of-care evidence offer for that specific injury?
• Given that the only published test of these two peptides together found no benefit over either one alone in rats, what is the argument for using them together at all?^[2]
• If the reasoning rests on thymosin β4's wound-healing trials, how does the fact that those trials used a different, larger molecule change it?^[5]
• Does a personal or family history of malignancy change the calculus, given that angiogenesis is the central proposed mechanism?^[8]
• What would show whether anything changed, rather than how it feels during a rehabilitation window when it was going to improve anyway? Imaging, load testing, a validated function score?
• If competing in a tested sport, what does this year's Prohibited List say, and who is the right person to ask?

Anti-doping status

Both components of this combination are prohibited in tested sport at all times, in and out of competition, under the World Anti-Doping Agency Prohibited List in force for 2026:

• BPC-157: section S0, non-approved substances. S0 covers any pharmacological substance that is not addressed by another section of the List and has no current approval by any governmental regulatory health authority for human therapeutic use, and BPC-157 is named there as an example. Every substance in this class is a Specified Substance.
• TB-500: section S2.3, growth factors and growth factor modulators. The List names "thymosin-β4 and its derivatives" and gives TB-500 as the example, within the class covering growth factors that affect muscle, tendon, or ligament protein synthesis, vascularization, and regenerative capacity. Substances in the S2 class are non-Specified Substances, which carries different sanctioning consequences from S0. That distinction is worth raising with a national anti-doping organization rather than settling it from a web page.

There is no in-competition-only carve-out for either one, and no threshold. A page named after a fictional healing factor is read disproportionately by people who compete, which is why this section exists and why the fact appears three times on this page.

The statuses above were read from the published Prohibited List itself rather than from the research literature, and that distinction is not pedantic here. A 2025 review of BPC-157 states in its own abstract that the compound was banned only temporarily in 2022 and is not currently listed by the World Anti-Doping Agency. That is false. It is named under S0 in the list in force today, and that parenthetical is the origin of a claim that still circulates widely.^[8] The review remains a reasonable survey of the preclinical work; it is not a source for anti-doping status, and neither is any other review.^[9] The List is reissued every year and its sections renumber, so a competing athlete should confirm the current year's list rather than this page.